Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Clicks Group Limited (CLS.JO)
Cape Town, ZA
Clicks Group Limited, a prominent retailer specializing in health, wellness, and beauty, operates extensively in South Africa and internationally through its various subsidiaries. The company's operations are segmented into Retail and Distribution. The Retail division encompasses a diverse portfolio of brands and services. Key among these is Clicks, a leading specialist in health, beauty, and homeware. This segment also includes Sorbet, a network of franchised hair and beauty salons, and 180 Degrees Marketing, a software development firm. The Body Shop, offering naturally-inspired luxury toiletries, cosmetics, gifts, and grooming products, is also part of this segment. Furthermore, Clicks Group provides a comprehensive array of mother-and-baby products under its Clicks Baby brand, covering hardware, accessories, health items, food, diapers, wipes, and toiletries. Specialized healthcare services, such as diabetic and travel clinics and wound management practices, are delivered through its M-KEM brand. The Distribution segment, operating primarily through its UPD brand, is dedicated to the wholesale supply of pharmaceutical products. This includes supplying retail pharmacies, private hospitals, dispensing doctors, and various other health stores. Established in 1968, the company was initially known as New Clicks Holdings Limited before officially adopting its current name, Clicks Group Limited, in June 2009. Its corporate headquarters are situated in Cape Town, South Africa.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.60% | -8.30% | -10.75% | -26.31% | -32.46% | -30.33% | -39.59% | +0.03% | -8.93% | +119.16% | +3,240.46% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | -1 |
| Hold | 2 | +1 |
| Sell | 0 | -1 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+12.9% ★ Q1'26: +22.4% (vs Q1'24)
-
EPS growth Medical - Pharmaceuticals: +20.2%+14.5% Q1'26: +22.7% (vs Q1'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+8.2% Q1'26: +2.8% (vs Q1'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+9.4% ★ Q1'26: +8.4% (vs Q1'24)
-
ROIC Medical - Pharmaceuticals: +6.1%+45.9% ★ Q1'26: +71.1% (vs Q1'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%-0.4% ★ Q1'26: -1.8% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.60× ★ Q1'26: 0.34× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Aug 2015 actual |
Aug 2016 actual |
Aug 2017 actual |
Aug 2018 actual |
Aug 2019 actual |
Aug 2020 actual |
Aug 2021 actual |
Aug 2022 actual |
Aug 2023 actual |
Aug 2024 actual |
Aug 2025 actual |
Aug 2026 9 Rev. Ana. 5 EPS Ana. |
Aug 2027 9 Rev. Ana. 6 EPS Ana. |
Aug 2028 8 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
22.07B
est: 22.15B (-0.4%)
|
24.17B
est: 24.83B (-2.7%)
|
26.81B
est: 26.87B (-0.2%)
|
29.24B
est: 29.40B (-0.6%)
|
31.35B
est: 31.77B (-1.3%)
|
33.89B
est: 34.37B (-1.4%)
|
37.34B
est: 37.53B (-0.5%)
|
39.59B
est: 41.00B (-3.4%)
|
41.62B
est: 41.41B (+0.5%)
|
45.44B
est: 45.96B (-1.1%)
|
51.29B
est: 48.74B (+5.2%)
|
51.58B
51.18B – 51.91B
+5.8% YoY
|
55.59B
55.02B – 56.12B
+7.8% YoY
|
59.82B
59.78B – 59.87B
+7.6% YoY
|
| EBITDA |
1.64B
est: 2.72B (-39.7%)
|
1.84B
est: 3.05B (-39.8%)
|
2.12B
est: 3.30B (-35.8%)
|
2.21B
est: 3.61B (-38.7%)
|
3.56B
est: 3.90B (-8.7%)
|
3.96B
est: 4.22B (-6.1%)
|
4.09B
est: 4.61B (-11.3%)
|
5.22B
est: 5.03B (+3.7%)
|
5.21B
est: 5.08B (+2.6%)
|
5.99B
est: 5.78B (+3.7%)
|
6.68B
est: 6.13B (+9.0%)
|
6.49B
6.44B – 6.53B
+5.8% YoY
|
6.99B
6.92B – 7.06B
+7.8% YoY
|
7.52B
7.52B – 7.53B
+7.6% YoY
|
| EBIT |
1.39B
est: 1.94B (-28.4%)
|
1.57B
est: 2.18B (-27.8%)
|
1.82B
est: 2.36B (-22.7%)
|
1.87B
est: 2.58B (-27.5%)
|
2.52B
est: 2.79B (-9.5%)
|
2.85B
est: 3.02B (-5.5%)
|
2.85B
est: 3.29B (-13.3%)
|
3.85B
est: 3.60B (+7.0%)
|
3.70B
est: 3.63B (+1.9%)
|
4.25B
est: 4.13B (+2.8%)
|
4.80B
est: 4.38B (+9.6%)
|
4.64B
4.60B – 4.67B
+5.8% YoY
|
5.00B
4.95B – 5.05B
+7.8% YoY
|
5.38B
5.37B – 5.38B
+7.6% YoY
|
| Net Income |
954.58M
est: 918.41M (+3.9%)
|
1.09B
est: 1.04B (+4.8%)
|
1.28B
est: 1.19B (+7.2%)
|
1.48B
est: 1.36B (+8.2%)
|
1.68B
est: 1.57B (+6.8%)
|
1.88B
est: 1.75B (+7.6%)
|
1.84B
est: 2.03B (-9.4%)
|
2.64B
est: 2.33B (+13.3%)
|
2.54B
est: 2.54B (+0.0%)
|
2.84B
est: 2.70B (+4.9%)
|
3.24B
est: 3.24B (+0.0%)
|
3.48B
3.42B – 3.53B
+7.4% YoY
|
3.79B
3.72B – 3.97B
+9.0% YoY
|
4.15B
4.09B – 4.41B
+9.5% YoY
|
| SGA |
2.87B
est: 2.85B (+0.9%)
|
4.61B
est: 3.19B (+44.3%)
|
3.64B
est: 3.45B (+5.5%)
|
4.04B
est: 3.78B (+7.0%)
|
3.55B
est: 4.08B (-13.0%)
|
3.61B
est: 4.42B (-18.2%)
|
5.87B
est: 4.82B (+21.8%)
|
6.31B
est: 5.27B (+19.8%)
|
392.29M
est: 5.32B (-92.6%)
|
—
est: 3.08B (-100.0%)
|
437.76M
est: 3.26B (-86.6%)
|
3.45B
3.43B – 3.47B
+5.8% YoY
|
3.72B
3.68B – 3.76B
+7.8% YoY
|
4.00B
4.00B – 4.01B
+7.6% YoY
|
| EPS |
3.97
est: 3.85 (+3.0%)
|
4.61
est: 4.38 (+5.3%)
|
5.40
est: 5.00 (+8.0%)
|
6.09
est: 5.72 (+6.4%)
|
6.75
est: 6.61 (+2.2%)
|
7.51
est: 7.33 (+2.5%)
|
7.44
est: 8.51 (-12.6%)
|
10.80
est: 9.77 (+10.5%)
|
10.42
est: 10.95 (-4.8%)
|
11.90
est: 11.41 (+4.3%)
|
13.63
est: 13.63 (+0.0%)
|
14.56
14.41 – 14.87
+6.8% YoY
|
16.19
15.68 – 16.72
+11.2% YoY
|
17.90
17.24 – 18.56
+10.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI South Africa ETF EZA | 1.10% | 6.03M | 0.59% |
| 2 | iShares MSCI South Africa UCITS ETF USD IRSA.L | 0.88% | 2.26M | 0.65% |
| 3 | Global X - Emerging Markets ex-China ETF EMM | 0.55% | 323.3K | 0.66% |
| 4 | Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (C) MSRU.L | 0.52% | 14.97M | 0.25% |
| 5 | Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (D) MSDU.L | 0.52% | 14.97M | 0.25% |
| 6 | Global X - Emerging Markets Great Consumer ETF EMC | 0.34% | 221.9K | 0.65% |
| 7 | VanEck Africa Index ETF AFK | 0.31% | 314.0K | 0.76% |
| 8 | Pictet Emerging Markets Rising Economies ETF RISE | 0.28% | 61.2K | 0.73% |
| 9 | Pacer Emerging Markets Cash Cows 100 ETF ECOW | 0.25% | 540.1K | 0.70% |
| 10 | Franklin EM Multi-Factor Equity UCITS ETF FREM.L | 0.25% | 214.1K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bertina D. Engelbrecht B.Proc | Chief Executive Officer & Executive Director | 21M | female |
| Gordon Traill | Chief Financial Officer, Chief Support Services Officer & Director | 12M | male |
| Annalize Barnard | Company Secretary | — | female |
| Bridget Ngwakwana Makhura | Chief people officer | — | female |
| Nina Hind | Head of Retail Finance | — | female |
| Rachel Wrigglesworth | Chief Commercial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLS.JO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
